B cell lymphoma 2/Bcl2

Rb, 0.5 ml Conc.

Artikelnummer:1-B0010-05
Menge:
Technische Daten
Lagerung AK:Store at 2 - 8 °C. Do not use after expiration date indicated on the vial.
Kontrolle:Tonsil
Zelluläre Lokalisation:Cytoplasmic
Fixierung:1) NOTOXhisto 2) Formalin
Anwendung AK:IHC(p),IHC(f)
Immunogen:Synthetic peptide of human Bcl-2
Ig Unterklasse:IgG
Spezies:Rabbit
Klon:Polyclonal
Format AK:Concentrate
Reaktivität AK:Human, others not tested.
Synonyme:Apoptosis regulator Bcl 2, Apoptosis regulator Bcl2, AW986256, B cell CLL/lymphoma 2, B cell leukemia/lymphoma 2, B cell lymphoma 2, Bcl 2, Bcl-2, Bcl2, BCL2 protein, C430015F12Rik, D630044D05Rik, D830018M01Rik, Leukemia/lymphoma, B-cell, 2, Oncogene B-cell leukemia 2.
Verfügbar in folgenden Ländern:world wide (except US)
Status:IVD
Beschreibung

This antibody recognizes the anti-apoptotic protein BCL2, which is useful in distinguishing between neoplastic and reactive follicular lymphoma (BCL2-negative). It indcates cancers of breast, prostate, ovary, endometrium and colon. A recently identified protein,designated Bax p21 (Bcl-associated X protein ), has extensive amino acid homology with Bcl-2. Overexpression of Bax accelerates apoptotic death induced by cytokine deprivation and it counters the death repressor activty of Bcl-2.

Literatur

[1] Hata AN, Engelman JA and Faber AC (2015): The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 5(5):475-87.
[2] Anderson MA, Huang D and Roberts A (2014): Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 51(3):219-27.
[3] Vogler M (2014): Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med. 2014:943648.

Kontakt